Renal pelvis adenocarcinoma

Summary

Renal pelvis adenocarcinoma (MONDO:0003205) is a disease. A subtype of renal cell carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	renal pelvis adenocarcinoma
Mondo ID	MONDO:0003205
DOID	DOID:4918
NCIT	C6143
UMLS	C1335748
MedGen	277590
GARD	0023410
Anatomy (UBERON)	UBERON:0001224
Is cancer (heuristic)	no

Also known as: adenocarcinoma of kidney pelvis · adenocarcinoma of renal pelvis · adenocarcinoma of the kidney pelvis · adenocarcinoma of the renal pelvis · kidney pelvis adenocarcinoma · kidney renal pelvis adenocarcinoma · renal pelvis adenocarcinoma

Disease family

This is a subtype of renal cell carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › adenocarcinoma › renal cell carcinoma › renal pelvis adenocarcinoma

Related subtypes (10): mucinous tubular and spindle renal cell carcinoma, Wolffian duct adenocarcinoma, collecting duct carcinoma, renal cell adenocarcinoma, cystic renal cell carcinoma, kidney medullary carcinoma, adrenal cortex carcinoma, nonpapillary renal cell carcinoma, MIT family translocation renal cell carcinoma, acquired cystic disease-associated renal cell carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.